Floatz logo

Capmatinib

MET Exon 14 Mutation

Sun Yat-sen UniversitySmall moleculePhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

12 Active assets in the MET Exon 14 Mutation cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Intergroupe Francophone de Cancerologie Thoracique
Phase 3B
Nivolumab
Intergroupe Francophone de Cancerologie Thoracique
Phase 3B
Pembrolizumab
Intergroupe Francophone de Cancerologie Thoracique
Phase 3B
Atezolizumab
Intergroupe Francophone de Cancerologie Thoracique
Phase 3B
Epirubicin
Intergroupe Francophone de Cancerologie Thoracique
Phase 3B

View all 12 →

Same molecule, other indications

Capmatinib is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
59 / 100
View asset →
neoplasmDormant
CCC
Indicative ·
55 / 100
View asset →
hepatocellular carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →